Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium tetrad for functional constipation in children
ChiCTR2500100662Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Bifidobacterium tetravaccine in functional constipation (FC) (8 arms), sponsored by Peking University Third Hospital. Primary endpoint: Change from baseline in mean weekly spontaneous bowel movements during weeks 4 to 8. Started Apr 2025; status: recruiting.
02
Drugs
Bifidobacterium tetravaccine
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on ChiCTR2500100662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100662.